All articles by  

  1. Summit begins dosing in Phase III trials of ridinilazole

    UK-based Summit Therapeutics has started dosing in its Phase III clinical trial of antibiotic ridinilazole for the treatment of Clostridium difficile…
    Read More…

    15 Feb
  2. Boehringer and Lilly report positive data from Tradjenta trial

    Boehringer Ingelheim and Eli Lilly have reported positive results from the CAROLINA cardiovascular outcomes trial of Tradjenta (linagliptin) in type…
    Read More…

    15 Feb
  3. Merck plans Phase III trials for Keytruda in prostate cancer

    Merck has announced plans to launch three pivotal Phase III clinical trials for its immunotherapy Keytruda as a combination treatment…
    Read More…

    15 Feb
  4. ADC Therapeutics starts dosing ADCT-402 plus Imfinzi in Phase I trial

    Swiss drug discovery company ADC Therapeutics has commenced dosing patients in a Phase I clinical trial assessing its ADCT-402 (loncastuximab…
    Read More…

    14 Feb
  5. Affinivax and Astellas begin Phase I/II trial of pneumococcal vaccine

    Affinivax and its development partner Astellas have commenced a Phase I/II clinical trial to investigate ASP3772 vaccine against infection caused by…
    Read More…

    14 Feb
  6. Innovent starts treatment in IBI101 monoclonal antibody trial

    Chinese biopharmaceutical firm Innovent Biologics has started treating patients in a Phase I clinical trial of its monoclonal antibody candidate IBI101. IBI101…
    Read More…

    14 Feb
  7. ReGenTree begins ARISE-3 trial of RGN-259 for dry eye

    Pharmaceutical firm ReGenTree has initiated a Phase III ARISE-3 clinical trial to evaluate drug candidate RGN-259 to treat patients with…
    Read More…

    13 Feb
  8. Gilead’s selonsertib fails in Phase III STELLAR-4 study for NASH

    Gilead Sciences has reported top-line results from the Phase III STELLAR-4 clinical trial of selonsertib involving patients with compensated cirrhosis…
    Read More…

    13 Feb
  9. Exelixis to assess new tumour-targeting candidate in Phase I trial

    Exelixis is set to commence a Phase I clinical trial to evaluate XL092 for the treatment of various cancer types….
    Read More…

    13 Feb
  10. Merck and Pfizer combination therapy improves kidney cancer survival

    Merck has reported positive results from an interim analysis of the KEYNOTE-426 trial evaluating its Keytruda in combination with Pfizer’s…
    Read More…

    12 Feb

Go Top